Owkin · 公司档案
Owkin · 法国/美国 · AI与模型数据
登记关注方向：多模态生物医学AI、联邦学习、药物发现。关注方向是目录字段；具体能力请核查下方来源与项目证据。
公开已核验进展
Owkin 与赛诺菲合作开发药物研发 AI 智能体
Fri Jun 05 2026 00:00:00 GMT+0000 (Coordinated Universal Time) · 1 条当前公开证据
据 Owkin 官方公告，与赛诺菲开展多年合作，共同开发生物医药 AI 智能体，安排包含五年许可。该信息属于商业研发安排。
Owkin 与阿斯利康签订三年 K Pro 许可安排
Wed May 13 2026 00:00:00 GMT+0000 (Coordinated Universal Time) · 1 条当前公开证据
据 Owkin 官方公告，与阿斯利康达成安排，基于三年 K Pro 许可开发生物医药 AI 智能体。不是已验证的临床效果。
合作、许可与并购时间线
Owkin 与赛诺菲合作开发药物研发 AI 智能体
Fri Jun 05 2026 00:00:00 GMT+0000 (Coordinated Universal Time) · 1 条当前公开证据
据 Owkin 官方公告，与赛诺菲开展多年合作，共同开发生物医药 AI 智能体，安排包含五年许可。该信息属于商业研发安排。
Owkin 与阿斯利康签订三年 K Pro 许可安排
Wed May 13 2026 00:00:00 GMT+0000 (Coordinated Universal Time) · 1 条当前公开证据
据 Owkin 官方公告，与阿斯利康达成安排，基于三年 K Pro 许可开发生物医药 AI 智能体。不是已验证的临床效果。
以上来自最新 2 条已核验进展。合作事件成立与模型效果、实验结果或临床进度分别需要证据。
公开原文线索
Estonia and Owkin Partner to Advance Sovereign AI in Biology
Owkin official newsroom · 行业原文收录 · 来源发布：Tue Sep 29 2026 00:00:00 GMT+0000 (Coordinated Universal Time) · 本站收录：Thu Oct 08 2026 09:08:00 GMT+0000 (Coordinated Universal Time)
Tallinn / Paris, 29 September 2026 – Estonia, led by the National Applied Research Center Metrosert, and Owkin today announced a collaboration to advance sovereign AI in biological and health research, working with Metro
Owkin to License K Pro and Multimodal Data to Servier to Advance Oncology Research
Owkin official newsroom · 行业原文收录 · 来源发布：Fri Sep 11 2026 00:00:00 GMT+0000 (Coordinated Universal Time) · 本站收录：Thu Oct 08 2026 09:08:48 GMT+0000 (Coordinated Universal Time)
NEW YORK & PARIS - September 11, 2026 — Owkin, the agentic AI company pioneering the first automated AI scientist to revolutionize drug discovery and development, today announced an agreement with Servier, an independent
Owkin to License K Pro AI Scientist and Multimodal Oncology and Immunology Data to Boehringer Ingelheim
Owkin official newsroom · 行业原文收录 · 来源发布：Wed Sep 02 2026 00:00:00 GMT+0000 (Coordinated Universal Time) · 本站收录：Thu Oct 08 2026 09:08:56 GMT+0000 (Coordinated Universal Time)
NEW YORK & PARIS — Owkin, the agentic AI company striving to transform drug discovery and development for biopharma, today announced a license agreement with Boehringer Ingelheim for K Pro, Owkin’s AI Scientist, together
Owkin and CRO Aviano Sign Master Partnership Agreement to Foster Collaborative Oncology Research
Owkin official newsroom · 行业原文收录 · 来源发布：Fri Aug 07 2026 00:00:00 GMT+0000 (Coordinated Universal Time) · 本站收录：Thu Oct 08 2026 09:09:15 GMT+0000 (Coordinated Universal Time)
PARIS & PORDENONE, Italy — Owkin, the agentic AI company pioneering the first autonomous AI scientist to revolutionize drug discovery and development, and the Centro di Riferimento Oncologico di Aviano (CRO), a leading I
Owkin to Integrate Kognitic's Clinical Trial Data Into K Pro Through New Collaboration
Owkin official newsroom · 行业原文收录 · 来源发布：Thu Aug 06 2026 00:00:00 GMT+0000 (Coordinated Universal Time) · 本站收录：Thu Oct 08 2026 09:09:24 GMT+0000 (Coordinated Universal Time)
NEW YORK & PARIS — Owkin, the agentic AI company pioneering Biological Artificial SuperIntelligence to revolutionize drug discovery and development, today announced a data collaboration with Kognitic to integrate Kogniti
Owkin to Build AI Agents as Part of a Multi-Year K Pro Collaboration with Sanofi
Owkin official newsroom · 行业原文收录 · 来源发布：Fri Jun 05 2026 00:00:00 GMT+0000 (Coordinated Universal Time) · 本站收录：Thu Oct 08 2026 09:08:10 GMT+0000 (Coordinated Universal Time)
NEW YORK & PARIS - 5th June, 2026 - Owkin, the agentic AI company pioneering Biological Artificial Superintelligence to transform drug discovery and development, today announced a multi-year collaboration with Sanofi to
Owkin and BeOne Medicines Sign Clinical Supply Agreement for Tislelizumab in INVOKE Trial of OKN4395
Owkin official newsroom · 行业原文收录 · 来源发布：Mon Jun 01 2026 00:00:00 GMT+0000 (Coordinated Universal Time) · 本站收录：Thu Oct 08 2026 09:08:24 GMT+0000 (Coordinated Universal Time)
BeOne Medicines will supply tislelizumab, its PD-1 inhibitor, to Owkin's ongoing INVOKE Phase 1a/1b trial of OKN4395 in patients with advanced solid tumors (NCT06789172). The agreement opens a combination arm pairing OKN
Owkin to Build AI Agents as Part of a Multi-Year K Pro License Agreement with AstraZeneca
Owkin official newsroom · 行业原文收录 · 来源发布：Wed May 13 2026 00:00:00 GMT+0000 (Coordinated Universal Time) · 本站收录：Thu Oct 08 2026 09:08:37 GMT+0000 (Coordinated Universal Time)
Owkin, the agentic AI company pioneering Biological Artificial Superintelligence to revolutionize drug discovery and development, today announced an agreement with AstraZeneca to build biopharma agents as part of their t
已验证的官方与订阅来源
- Owkin official newsroom · 采集已启用 · 最近成功 Thu Oct 08 2026 13:08:12 GMT+0000 (Coordinated Universal Time)
来源验证与持续采集分别显示；原文收录不自动成为已核验事件。
专题指南：从原文到判断
按任务比较模型，按证据追踪合作；每篇保留原始出处与更新日期。
虚拟细胞、AI 模型与公司：应该怎样比较？
按输入、输出、任务和验证条件比较单细胞模型、结构预测与蛋白设计，并区分模型论文与公司能力。
阅读指南 · 更新 2026-10-08
AI 制药公司合作时间线：从公告读到证据
用真实官方公告区分合作主体、首付款、条件性里程碑和研发进度，并建立可追溯的合作时间线。
阅读指南 · 更新 2026-10-08
每周 AI 制药信息怎么读：公司动态、研究进展与覆盖缺口
建立每周阅读顺序，分清公告、论文与临床结果；理解本站本周收录的时间窗口、分母和来源覆盖。
阅读指南 · 更新 2026-10-08